阿仑膦酸钠防治绝经后骨质疏松的疗效

目的观察国产阿仑膦酸钠防治绝经后骨质疏松症的疗效。方法56例50～74岁骨量减少或骨质疏松的绝经后妇女随机分为两组(每组28人),每日给予阿仑膦酸钠10mg/d或安慰剂,两组均加服碳酸钙片和维生素D,治疗6个月。试验前后用双能X线吸收法检测腰椎和髋部的骨矿密度(bonemineraldensity,BMD),同时检测骨转换的生化指标。结果与治疗前相比,治疗组腰椎BMD平均增加5%(P<0.01),对照组各部位的BMD均下降(P<0.05);治疗组骨吸收指标和骨形成指标均降低,其中NTx下降最明显,近75.7%(P<0.001),而对照组却无显著性变化。结论国产阿仑膦酸钠能降低绝经后妇女的骨转换,增加骨量。     

龟鹿二仙膏联合阿仑膦酸钠片治疗绝经妇女骨质疏松症的临床研究

目的观察龟鹿二仙膏联合阿仑膦酸钠片治疗绝经妇女骨质疏松症的临床疗效,并探讨其作用机制。方法选取76例绝经妇女骨质疏松症患者,随机分为对照组和观察组,每组40例。对照组采用阿仑膦酸钠片口服治疗,观察组在对照组治疗基础上予以龟鹿二仙膏口服治疗。比较2组治疗前后腰椎及股骨近端BMD、血清IGF-1和TNF-α水平变化及临床疗效。结果治疗前,2组患者腰椎及股骨近端BMD、血清IGF-1和TNF-α水平比较,差异无统计学意义(P0.05);治疗后,2组患者腰椎及股骨近端BMD均较治疗前明显升高,且观察组改善程度显著优于对照组(P0.05);治疗后,2组患者血清IGF-1均较治疗前明显升高,TNF-α均较治疗前明显降低,且观察组改善程度显著优于对照组(P0.05);治疗后,观察组临床治疗总有效率为92.11%,显著高于对照组的68.42%(P0.05)。结论应用龟鹿二仙膏联合阿仑膦酸钠片治疗绝经妇女骨质疏松症可显著升高腰椎及股骨近端BMD,改善血清IGF-1及TNF-α水平,提高临床疗效,值得推广应用。     

甲状旁腺素、降钙素和阿仑膦酸钠治疗绝经后妇女骨质疏松症的疗效比较

目的：比较甲状旁腺素、鲑降钙素、阿仑膦酸钠对绝经后妇女骨质疏松症的疗效.方法：对110位确诊患有骨质疏松症的绝经后妇女进行随机分组,分别接受甲状旁腺素20 μg/d皮下注射（36例）或鲑降钙素200 IU/d鼻内给药（36例）或阿仑膦酸钠70 mg/周口服（38例）,共24周.测定主要指标为从基线到终点腰椎骨密度（BMD）变化量;次要指标为从基线到终点全髋BMD变化量及血清骨钙素含量的变化.对结果进行分析比较.结果：共100例患者完成治疗,10例患者中途退出研究.甲状旁腺素组（n=36）在增加患有骨质疏松症的绝经后中国妇女腰椎BMD及血清骨钙素含量方面明显优于降钙素组（n=31）及阿仑膦酸钠组（n=33）,在改变全髋BMD方面与降钙素组及阿仑膦酸钠组无明显差别.结论：与降钙素及阿仑膦酸钠相比,甲状旁腺素在促进患有骨质疏松症的绝经后妇女的骨形成方面的效果更佳.     

伊班膦酸钠与阿仑膦酸钠对绝经后骨质疏松疗效的比较

目的:评价伊班膦酸钠与阿仑膦酸钠对绝经后骨质疏松的疗效.方法:绝经后骨质疏松妇女32例,随机分为2组,所有患者每天在接受元素钙500 mg和维生素D 200 IU治疗的同时,分别接受伊班膦酸钠和阿仑膦酸钠治疗,其中伊班膦酸钠150 mg每月1次;阿仑膦酸钠70 mg每周1次.2种药物治疗时间均为1年.通过双能X线吸收仪(DEXA)及血清Ⅰ型胶原交联C端肽(CTX-1)观察治疗中及治疗后的骨量及骨转换的变化.结果:2组患者经过1年治疗,与用药前比较,腰椎(L2-4)骨量显著上升(P＜0.05),髋部骨量增加但没有统计学意义(P＞0.05):其中伊班瞵酸钠治疗组腰椎L2-4、股骨颈、股骨大转子和全髋骨密度分别上升15.34%、4.15%、5.05%和2.49%;阿仑瞵酸钠治疗组分别上升14.50%、4.42%、1.18%和2.64%;破骨指标血清CTX-1在2组均明显下降(P＜0.05).2组之间各时点的各部位骨密度值、血清CTX-1值均无统计学差异(P＞0.05).结论:伊班膦酸钠服用方便,且对于绝经后骨质疏松的治疗效果与阿仑膦酸钠无明显差异.     

阿仑膦酸钠加雌孕激素治疗绝经后骨量减少及观察消化道副作用

目的评价阿仑膦酸钠加雌孕激素，阿仑膦酸钠治疗绝经后骨质疏松症、骨量减少临床疗效及消化道副作用。方法92例绝经后骨质疏松症、骨量减少女性作为期1年随机双盲，安慰剂平行对照研究。用药1年比较治疗前后SOS、T值和消化道副作用。治疗前，治疗后1年应用超声定量骨密度仪进行胫骨SOS、T值测定，记录病人腹痛，恶心，消化不良情况。结果用药组A组、B组治疗1年胫骨SOS分别平均增加9．87％、5．69％，T值分别平均上升80．67％，59．56％，分别与C组比较差异有显著性（P〈0．01）。A组、B组治疗半年，分别出现腹痛3．2％，6．7％，发生恶心3．2％、3．3％，明显消化不良3．2％、3．3％，2组分别与C组比较差异无显著性（P〉0．05）;A组、B组治疗1年分别出现腹痛3．2％，6．7％，发生恶心3．2％，3．3％，明显消化不良6．5％，6．7％，分别与C组比较差异无显著性（P〉0．05）。结论阿仑膦酸钠加雌孕激素、单用阿仑膦酸钠治疗绝经后骨质疏松症，骨量减少有效且消化道副作用较轻。     

阿仑膦酸钠联合骨化三醇治疗绝经后妇女骨质疏松症的疗效观察

目的探讨阿仑膦酸钠联合骨化三醇治疗绝经后妇女骨质疏松症的临床疗效。方法将32例绝经后妇女骨质疏松症患者随机分为A及B组,各16例。A组口服阿仑膦酸钠片和骨化三醇片,B组仅服骨化三醇片。观察两组治疗前及治疗6个月后疼痛改善、腰椎及股骨颈的骨密度（BMD）、血钙和血磷等生化指标的变化。结果 A组治疗后疼痛评分较治疗前明显改善（〈0.05）,B组无明显变化（〉0.05）。两组治疗后BMD均有明显上升,但A组明显大于B组（〈0.01）。两组治疗前后血钙及血磷均在正常范围。结论阿仑膦酸钠联合骨化三醇治疗绝经后妇女骨质疏松症疗效确切,明显优于单用骨化三醇,值得推广应用。     

利塞膦酸钠对绝经后骨质疏松症妇女血清BALP和尿HOP的影响

目的 用利塞膦酸钠治疗绝经后骨质疏松妇女6个月，观察其对骨密度（BMD）、血清骨特并性碱性磷酸酶、尿羟脯氨酸的影响。方法 将46例绝经后骨质疏松妇女每日早饭前半小时服用5mg利塞膦酸钠和凯思力D1片，疗程6个月；另选25名健康的绝经女性作为对照组。治疗前后分别用美国DPX双能X线骨密度仪测骨密度，免疫渗滤和全血干化学技术测定骨特异性碱性磷酸酶，化学比色法测尿羟脯氨酸；同时观察骨痛、骨折及胃肠道等副反应情况。结果 利塞膦酸钠治疗后腰椎2～4、股骨颈BMD值显著升高，Wards三角区BMD呈增加趋势；血清骨特异性碱性磷酸酶及尿羟脯氨酸明显下降；与治疗前相比，利塞膦酸钠治疗后还可缓解骨质疏松引起的腰背痛等症状，增加关节活动度。结论 利塞膦酸钠可提高预绝经后骨质疏松妇女骨密度，降低血清骨特异性碱性磷酸酶及尿羟脯氨酸。     

序贯应用甲状旁腺素和二膦酸盐预防激素性骨质疏松的实验研究

目的 研究序贯应用甲状旁腺素和阿仑膦酸钠对类固醇兔骨质疏松的影响。方法 将成年新西兰大白兔30只随机分为3组：对照组、激素模型组、甲状旁腺素和阿仑膦酸钠治疗组,9周后取股骨和腰椎行超声骨密度测量,再行股骨扭转和腰椎压缩试验,检测血清钙、磷和碱性磷酸酶。结果 激素模型组的BUA,SOS值和骨生物力学参数较对照组有明显减少（P〈0．01）,血清磷和碱性磷酸酶减少;甲状旁腺素和阿仑膦酸钠治疗组的BUA,SOS值和骨生物力学参数较激素模型组增加（P〈0．05）,血清磷和碱性磷酸酶增加。结论 序贯应用甲状旁腺素和阿仑膦酸钠可以减少类固醇兔骨量的丢失,预防骨质疏松的发生。     

阿仑膦酸钠对绝经后妇女骨质疏松症治疗及骨折的预防作用

目的观察阿仑膦酸钠对绝经后妇女骨质疏松症的治疗疗效及骨折的预防作用。方法绝经后骨质疏松妇女165例,随机分为2组:治疗组83例和对照组82例。2组均应用碳酸钙600 mg口服,每晚1次,α-活性维生素D3 0.25μg口服,每日2次。治疗组加阿仑膦酸钠70 mg,每周1次口服。各组用药前及治疗2年后分别检测腰椎及左侧髋部双能X线骨密度检查(BMD)。观察治疗期间骨痛改善情况;随访骨折事件发生率。结果阿仑膦酸钠治疗组治疗2年,腰椎及左侧髋部BMD均有不同程度提高,腰椎BMD上升15.7%,股骨颈BMD值上升20.8%,与治疗前相比有统计学意义(P<0.05)。对照组骨密度则不同程度下降,但无统计学意义(P>0.05),两组相比有统计学意义(P<0.01)。治疗组治疗4周时疼痛缓解有效率达80.7%,治疗3个月时疼痛缓解有效率达89.2%,而对照组分别为24.4%和30.5%,两组之间比较具有统计学意义(P分别为0.021和0.029)。治疗组仅发生1例骨折事件,对照组发生7例骨折事件,两组相比差异有统计学意义(P<0.05)。两组治疗均无明显不良反应。结论阿仑膦酸钠治疗绝经后妇女骨质疏松症疗效肯定,对骨折有明显预防作用。     

左归丸联合阿仑膦酸钠片治疗绝经后骨质疏松症的临床研究

目的探讨左归丸联合阿仑膦酸钠片治疗绝经后骨质疏松症的临床疗效及作用机制。方法选取2016年8月—2018年10月本院妇科收治的绝经后骨质疏松症患者102例,按照随机数字表法分为观察组和对照组,每组51例。对照组患者予以阿仑膦酸钠片口服治疗,观察组患者在对照组治疗基础上予以左归丸口服。比较2组患者治疗前后腰椎及股骨近端骨密度(BMD)水平变化,比较2组患者治疗前后血清抗酒石酸酸性磷酸酶-5b(TRACP-5b)及组织蛋白酶K(CTSK)水平变化,比较2组患者临床疗效。结果治疗后,2组患者腰椎及股骨近端BMD水平均较治疗前明显升高,且观察组显著高于对照组(P0.05);2组患者血清TRACP-5b及CTSK水平均较治疗前明显下降,且观察组显著低于对照组(P0.05);观察组患者临床治疗总有效率为92.16%,显著高于对照组的70.59%(P0.05)。结论应用左归丸联合阿仑膦酸钠片治疗绝经后骨质疏松症患者可显著升高腰椎及股骨近端BMD水平,提高临床疗效,其治疗机制可能与降低血清TRACP-5b及CTSK水平有关。     

阿伦膦酸钠对绝经后骨量减少和骨质疏松妇女骨密度变化的影响

目的　观察绝经后骨量减少和骨质疏松妇女在阿伦膦酸钠 (福善美 )治疗和停药后的骨密度变化。方法　 4 0例绝经后骨质疏松和骨量减少的妇女 ,每日口服福善美 10mg和元素钙 5 0 0mg,分为服药 6个月组 2 5例 ,服药 12个月组 15例。停药后仅应用元素钙 5 0 0mg/d。观察服药期间和停药后的骨密度变化。结果　服药 6个月组 :腰椎 2～ 4和髋部的BMD值于服药 6个月时较服药前均有明显升高 ,其中腰椎 2～ 4升高 5 3% (P <0 0 0 1)。停药 13± 4个月后 ,腰椎 2～ 4和髋部的BMD值与服药 6个月时比较未见降低 ,大转子部位的BMD值较服药 6个月还有进一步升高。服药 12个月组 ,服药 6个月时 ,除Wards三角外 ,其他 3个部位的BMD值较用药前明显升高 ,其中腰椎 2～ 4升高4 2 % (P <0 0 0 1) ;服药 12个月时 ,腰椎 2～ 4的BMD较服药前升高 6 1% (P <0 0 0 1) ,而髋部的BMD较服药前未见明显改变。停药 2 3± 7个月后 ,腰椎和髋部的BMD与服药 12个月时相比均无明显变化。结论　阿伦膦酸钠治疗绝经后骨量减少和骨质疏松妇女 ,可以明显升高腰椎及髋部的骨密度 ,以腰椎部位升高更显著 ,停药后骨密度可维持 13～ 2 3个月。     

Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women△

Objective To investigate the relationship between geranylgeranyl pyrophosphate synthase (GGPPS) genepolymorphisms and bone response to alendronate in Chinese osteoporotic women.
Methods A total of 639 postmenopausal women with osteoporosis or osteopenia were included and randomly received treatment of low dose (70 mg per two weeks) or standard dose (70 mg weekly) of alendronate for one year. The six tag single nucleotide polymorphisms ofGGPPSgenewere identified. Bone mineral density (BMD), serum cross-linked C-telopeptide of type I collagen (β-CTX), and total alkaline phosphatase (ALP) were measured before and after treatment.GGPPS gene polymorphisms and the changes of BMD and bone turnover markers after treatment were analyzed.
Results rs10925503 polymorphism ofGGPPS gene was correlated to serumβ-CTX levels at baseline, and patients with TT genotype had significantly higher serumβ-CTX level than those with TC or CC genotype (allP<0.05). No correlation was found between polymorphisms ofGGPPS gene and serum total ALP levels, as well as BMD at baseline. After 12 months of treatment, lumbar spine and hip BMD increased and serum bone turnover markers decreased significantly (P<0.01), and without obvious differences between the low dose and standard dose groups (allP>0.05). However,GGPPSgene polymorphisms were uncorrelated to percentage changes of BMD, serum total ALP, andβ-CTX levels (allP>0.05).
ConclusionGGPPS gene polymorphisms are correlated to osteoclasts activity, but all tag single nucleotide polymorphisms ofGGPPS gene have no influence on the skeletal response to alendronate treatment.     

强骨膏方改善绝经后骨量减少患者生活质量的临床疗效评价

目的 评价强骨膏方对绝经后骨量减少患者生活质量的影响。 方法 纳入2015年10月—2016年12月在浙江中医药大学附属第二医院骨伤科就诊的120例绝经后骨量减少妇女为研究对象,平均年龄(57.67±2.86)岁,按随机数表法分为强骨膏方组(60例)和阿仑膦酸钠组(60例),均干预1年。采用电化学发光免疫分析技术测量血清Ⅰ型原胶原氨基端肽(PINP)及Ⅰ型胶原羧基端肽交联(β-CTX)等骨转换指标水平。用双能X线骨吸收仪测量腰椎、髋部骨密度。采用SF-36量表(中文版)分别于治疗前、治疗1年后对患者生活质量改善情况进行评估,评分量表由36个详细条目组成。 结果 共108例患者完成研究,强骨膏方组56例,阿仑膦酸钠组52例。治疗1年后,2组组内患者血清PINP、β-CTX水平均较治疗前显著降低,且治疗后组间血清PINP、β-CTX水平及其平均百分比变化差异均有统计学意义(均P<0.001);2组组内治疗前后患者髋部、腰椎骨密度值比较,差异均无统计学意义(均P>0.05),但2组治疗后组间腰椎(P<0.001)、髋部(P=0.022)骨密度平均百分比变化差异均有统计学意义,且强骨膏方组优于阿仑膦酸钠组。治疗前,强骨膏方组和阿仑膦酸钠组患者的SF-36评分分别为(112.38±2.13)分、(111.79±2.06)分,2组间差异无统计学意义(P=0.147);2组组内治疗前后比较,差异均有统计学意义(均P<0.001),2组于治疗1年后组间比较,差异有统计学意义(P<0.001),且强骨膏方组生活质量评分明显高于阿仑膦酸钠组。 结论 采用强骨膏方治疗不仅能够显著降低绝经后骨量减少妇女血清骨转换水平改善腰椎、髋部骨密度,并能显著提高患者生活质量。      

女性骨面积大小与骨密度的关系

目的 了解女性骨面积大小(BAS)和骨矿物质密度(BMD)随年龄的变化趋势以及BAS与BMD的关系.方法采用Hologic QDR-2000双能X线吸收仪测量3390例20～84岁女性L1～L4后前位和左侧股骨近端(全髋部、股骨颈、大转子和转子间)骨矿物质含量(BMC)、BAS和BMD.结果L1～L4的BMC、BAS和BMD峰值均出现在30～34岁组,随后逐年下降,三者变化趋势一致;而股骨近端各部位BMC、BAS和BMD的变化趋势不同,BMC峰值出现在40～44岁组,BAS有随年龄增长逐渐增大的趋势,BMD峰值出现在20～24岁组.L1～L4的BAS与年龄呈负相关(r=0.362,P＜0.05);全髋部和大转子部位的BAS与年龄呈正相关,但相关系数较低;股骨颈和转子问的BAS与年龄不相关(P值均＞0.05).L1～L4(r=0.521)和近端全髋部(r=0.083)的BMD均与BAS呈正相关(P值均=0.000),股骨颈的BMD与BAS呈负相关(r=-0.102,P=0.000),大转子和转子间的BMD均与BAS不相关(P值均＞0.05).结论 使用面积BMD作为骨质疏松的诊断标准时,应该重视不同骨骼部位BAS的影响,是否使用体积BMD作为诊断标准是值得探讨的问题.     

Benefit period using alendronate to increase bone mineral density in women with osteoporosis?

Background Alendronate, a nitrogen-containing bisphosphonate is a specific inhibitor of bone resorption and now in the forefront of treatment of osteoporosis. In this study, we reported a significant increase in bone mineral density (BMD) of the spine and the hip in postmenopausal women taking alendronate at 10mg/d for 1,2 and 3 years. Methods Participants had received daily, oral, 10mg dose of alendronate for one to three years and placed into one of three groups according to alendronate treatment duration: 41 women received alendronate for 1 year (group Ⅰ) , 46 received alendronate for 2 years (group Ⅱ) , and 30 received alendronate tor 3 years (group Ⅲ). Measurements of bone density had been made by dual energy X-ray absorbtiometry once each year.Results The differences in L2-L4,L2, L4, femoral neck and trochanter BMD values before and after treatment for first group were significantly different. In second group, significant differences between initial and after treatment were found at the other sites except at the Ward‘s triangle. In the third group, only a significant increase in the L2-L4, L2, L3, L4, trochanter BMD values between before treatment and at the end of third year was found. Comparisons between groups were performed with Student‘s t test. ANOVA was used to test the age, menopause age, menopause duration and initial BMD values between the three groups. Calculated P values of less than 0.05 were considered statistically significant.Conclusions Alendronate had increased BMD significantly at the spine and hip in postmenopausal women over three years. Increases of BMD in third group were significant during the first and second years. However, continued therapy with alendronate had been required to maintain the gain in BMD over the third year.     

2型糖尿病患者骨密度分析

目的研究2型DM患者骨密度的改变.方法应用DEXA测定了173例2型DM患者和101例健康对照组L2～4及股骨近端BMD.结果 (1)65岁以上年龄组的男性2型DM患者L2～4、Neck、Ward's区、Troch的BMD较同龄健康对照组显著降低(P＜0.01、P＜0.05);55～65岁年龄组L2～4、Ward's区BMD与同龄健康对照组比较也有显著差异(P＜0.05).(2)55岁以上的女性2型DM患者L2～4、Neck、Ward's区的BMD较同龄健康对照组显著降低(P＜0.01、P＜0.05).结论 (1)不同性别、年龄的2型DM患者各部位BMD改变不同.(2)55岁以上年龄组的2型DM患者腰椎、股骨Ward's区BMD降低明显.     

Osteoporosis risk factors and association with somatotypes in males

BACKGROUND: Osteoporosis is a systemic and metabolic skeletal disease characterized by reduced bone mass, changes in microarchitecture, and consequential increased fracture risk. Previous reports described a relationship between bone content with fat mass and lean body mass. In this study, we assessed osteoporosis risk factors and the association with somatotypes in males aged 45-65 years. METHODS: Standard axial spine and proximal femur bone mineral density (BMD) were measured using dual x-ray (DXA) absorptiometry in 70 healthy men. Heath-Carter procedure was followed to assess individual's somatotype. RESULTS: All body types were grouped as endomorphy, mesomorphy, and ectomorphy. Moderate to weak correlations were found between lumbar BMD with endomorphy and mesomorphy. Negative correlation was found between lumbar BMD and ectomorphy. Total femur BMD correlated positively with endomorphy and mesomorphy and negatively correlated with ectomorphy. Body mass index correlated weakly with lumbar, femur neck, and total femur BMD. Multiple regression analysis revealed that endomorphy was significantly related to BMD measurements at lumbar spine (standardized coefficient, SC = 0.51, p = 0.001), femur neck (SC = 0.52, p = 0.001), and total femur BMD (SC = 0.41, p = 0.01). Lumbar BMD and age, hand grip strength, smoking, tea and coffee consumption, calorie expenditure, calcium intake, PTH, albumin, total protein, sex hormone-binding globulin, and testosterone were not significantly correlated. CONCLUSIONS: Endomorphy seems related to high BMD values at the lumbar spine and the proximal femur in middle-aged men. Somatotype together with daily calorie expenditure may be taken into account when assessing risk factors for male osteoporosis.     

绝经前后女性身体成分与骨密度相关性分析

目的探讨绝经前后女性身体成分与骨密度（BMD）的关系。方法采用LunaProdigy双能X线BMD检测仪对健康体检的绝经前女性22例、绝经后女性62例进行腰椎正位,左髋和全身BMD检测和身体成分检测。结果①绝经前组股骨各部位、腰椎（L1—L4）和全身BMD,以及全身和躯干肌肉显著高于绝经后组（P〈0．05,或P〈0．01）;②绝经前组全身、躯干和左大腿肌肉均与全身BMD呈显著正相关,身棒成分与腰椎和股骨BMD无显著相关性（P〉0．05）;③绝经后组全身和躯干的脂肪、肌肉分别与L3、L4、股骨大粗隆、股骨干和全身BMD均呈显著正相关（P〈0．05,或P〈0．01）;全身脂肪、肌肉,躯干脂肪分别与L1、L2和股骨颈BMD均呈显著正相关（P〈0．05,或P〈0．01）;躯干肌肉与股骨大粗隆骨密度呈显著正相关（P〈0．05）;左大腿成份与上述部位骨密度均无显著相关性。结论绝经前女性全身BMD与肌肉成分密切相关。绝经后女性全身和躯干脂肪、肌肉与腰椎、股骨和全身BMD密切相关,但脂肪成分似乎更明显。